Medicare Enrolled
Dr. Mark Romer, MD
Medical Oncology · Dayton, OH
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Romer from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Romer?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Romer
Dr. Mark Romer is a medical oncology specialist in Dayton, OH, with 20 years of NPI registration. Based on federal Medicare data, Dr. Romer performed 62,518 Medicare services across 1,537 unique beneficiaries.
Between the years covered by Open Payments, Dr. Romer received a total of $10,769 from 88 pharmaceutical and/or device companies across 673 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Romer is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 5% volume in OH
$10,769 industry payments
Medicare Practice Summary
Medicare Utilization ↗62,518
Medicare services
Top 5% in OH for medical oncology
1,537
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,126 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 12,200 | $43 | $99 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
10,305 | $2 | $8 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
9,150 | $0 | $1 |
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
9,000 | $1 | $2 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
6,000 | $0 | $0 |
| Denosumab injection (Prolia/Xgeva) | 5,040 | $19 | $37 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
3,500 | $0 | $0 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
2,390 | $36 | $86 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,318 | $0 | $0 |
| Anti-nausea injection (Aloxi/palonosetron) | 901 | $1 | $3 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
547 | $89 | $207 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
351 | $57 | $140 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
248 | $93 | $403 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
214 | $11 | $64 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
155 | $10 | $45 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
124 | $59 | $110 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
121 | $21 | $100 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
115 | $43 | $181 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
105 | $1 | $1 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
93 | $6 | $50 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
71 | $20 | $92 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
69 | $14 | $61 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 66 | $135 | $457 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
54 | $128 | $281 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
47 | $752 | $2,196 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
47 | $47 | $198 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
42 | $41 | $166 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 37 | $613 | $800 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
33 | $24 | $84 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
30 | $113 | $320 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
29 | $2 | $5 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
24 | $86 | $156 |
| New patient office visit, complex (60-74 min) | 17 | $152 | $402 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
16 | $80 | $470 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
16 | $57 | $192 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
16 | $90 | $222 |
| Transitional care management, high complexity Coordination of care for a patient transitioning from a short-term hospital stay or other facility to home or another care setting. This service addresses a high-complexity medical problem. |
14 | $196 | $448 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
13 | $149 | $484 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
19.2% high complexity
78.7% medium
2.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$10,769
Total received (2018-2024)
Avg $1,538/year across 7 years
Top 26% in OH for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
88
Companies
673
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,700 (99.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$69 (0.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,105
2023
$2,699
2022
$1,440
2021
$478
2020
$347
2019
$1,379
2018
$1,320
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$269
Novartis Pharmaceuticals Corporation
$253
AstraZeneca Pharmaceuticals LP
$232
PFIZER INC.
$230
Daiichi Sankyo Inc.
$214
Janssen Biotech, Inc.
$197
Merck Sharp & Dohme LLC
$191
Lilly USA, LLC
$134
Celgene Corporation
$113
Incyte Corporation
$112
Gilead Sciences, Inc.
$80
Genentech USA, Inc.
$73
Alexion Pharmaceuticals, Inc.
$70
TAIHO ONCOLOGY, INC.
$55
Zimmer Biomet Holdings, Inc.
$55
ARRAY BIOPHARMA INC
$52
GENZYME CORPORATION
$52
Bayer Healthcare Pharmaceuticals Inc.
$52
TerSera Therapeutics LLC
$45
Cumberland Pharmaceuticals, Inc.
$39
Stemline Therapeutics Inc.
$37
Astellas Pharma US Inc
$34
GlaxoSmithKline, LLC.
$34
Myriad Genetic Laboratories, Inc.
$33
Kite Pharma, Inc.
$30
Pharmacosmos Therapeutics Inc.
$27
Sumitomo Pharma America, Inc.
$25
Mirati Therapeutics, Inc.
$22
Boehringer Ingelheim Pharmaceuticals, Inc.
$21
SUN PHARMACEUTICAL INDUSTRIES INC.
$20
SOBI, INC
$19
Sandoz Inc.
$19
Blueprint Medicines Corporation
$18
Takeda Pharmaceuticals U.S.A., Inc.
$17
Adaptive Biotechnologies Corporation
$17
Legend Biotech USA Inc.
$17
JAZZ PHARMACEUTICALS INC.
$17
Rigel Pharmaceuticals, Inc.
$16
Regeneron Healthcare Solutions, Inc.
$16
ADC Therapeutics America, Inc.
$16
Sirtex Medical Inc
$16
Helsinn Therapeutics (U.S.), Inc.
$16
Azurity Pharmaceuticals, Inc.
$16
SpringWorks Therapeutics, Inc.
$15
Octapharma USA, Inc.
$15
Amneal Pharmaceuticals LLC
$14
E.R. Squibb & Sons, L.L.C.
$14
Tempus AI, Inc
$13
Kyowa Kirin, Inc.
$13
Top 3 companies account for 24.3% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$1,068
PFIZER INC.
$875
Merck Sharp & Dohme LLC
$594
Janssen Biotech, Inc.
$486
Daiichi Sankyo Inc.
$479
Pharmacyclics LLC, An AbbVie Company
$475
AstraZeneca Pharmaceuticals LP
$441
Celgene Corporation
$374
E.R. Squibb & Sons, L.L.C.
$352
GENZYME CORPORATION
$328
Lilly USA, LLC
$288
ABBVIE INC.
$269
Incyte Corporation
$227
Gilead Sciences, Inc.
$195
TerSera Therapeutics LLC
$189
Genentech USA, Inc.
$186
Amgen Inc.
$180
EISAI INC.
$179
Boehringer Ingelheim Pharmaceuticals, Inc.
$160
Bayer Healthcare Pharmaceuticals Inc.
$149
Takeda Pharmaceuticals U.S.A., Inc.
$142
JAZZ PHARMACEUTICALS INC.
$141
Regeneron Healthcare Solutions, Inc.
$135
Eisai Inc.
$129
Astellas Pharma US Inc
$126
Bayer HealthCare Pharmaceuticals Inc.
$108
Myriad Genetic Laboratories, Inc.
$103
ARRAY BIOPHARMA INC
$98
GlaxoSmithKline, LLC.
$90
TAIHO ONCOLOGY, INC.
$77
Foundation Medicine, Inc.
$77
Sun Pharmaceutical Industries Inc.
$77
Clovis Oncology, Inc.
$71
Alexion Pharmaceuticals, Inc.
$70
Kite Pharma, Inc.
$68
Ipsen Biopharmaceuticals, Inc
$65
Mirati Therapeutics, Inc.
$62
CTI BioPharma Corp.
$62
BeiGene USA, Inc.
$60
Adaptive Biotechnologies Corporation
$59
TESARO, Inc.
$58
Puma Biotechnology, Inc.
$57
Zimmer Biomet Holdings, Inc.
$55
Rigel Pharmaceuticals, Inc.
$53
Octapharma USA, Inc.
$53
Stemline Therapeutics Inc.
$53
Pharmacyclics LLC, an AbbVie Company
$51
Taiho Oncology, Inc.
$49
Helsinn Therapeutics (U.S.), Inc.
$47
Merck Sharp & Dohme Corporation
$45
SERVIER PHARMACEUTICALS LLC
$43
Lexicon Pharmaceuticals, Inc.
$43
Genmab U.S., Inc.
$41
Sumitomo Pharma America, Inc.
$39
Cumberland Pharmaceuticals, Inc.
$39
EMD Serono, Inc.
$37
SOBI, INC
$36
Mylan Institutional Inc.
$33
AbbVie Inc.
$33
EUSA Pharma (US) LLC
$33
ADC Therapeutics America, Inc.
$32
Aurobindo Pharma USA, Inc.
$32
Kyowa Kirin, Inc.
$31
Array BioPharma Inc.
$30
Pharmacosmos Therapeutics Inc.
$27
Seagen Inc.
$26
ACCORD HEALTHCARE, INC.
$25
Janssen Scientific Affairs, LLC
$24
Janssen Pharmaceuticals, Inc
$24
Apellis Pharmaceuticals, Inc.
$20
SUN PHARMACEUTICAL INDUSTRIES INC.
$20
Sandoz Inc.
$19
PharmaEssentia USA Corporation
$19
Karyopharm Therapeutics Inc.
$18
Tolmar, Inc.
$18
Blueprint Medicines Corporation
$18
Deciphera Pharmaceuticals Inc.
$18
Verastem, Inc.
$17
Legend Biotech USA Inc.
$17
Sirtex Medical Inc
$16
Azurity Pharmaceuticals, Inc.
$16
SpringWorks Therapeutics, Inc.
$15
Alnylam Pharmaceuticals Inc.
$15
Teva Pharmaceuticals USA, Inc.
$14
Amneal Pharmaceuticals LLC
$14
Tempus AI, Inc
$13
Exelixis Inc.
$11
NOVARTIS PHARMACEUTICALS CORPORATION
$7
Top 3 companies account for 23.6% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · ALPROLIX · ALUNBRIG · AVASTIN · AYVAKIT · Alecensa · Aliqopa · Avastin · BENDEKA · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Braftovi · CABLIVI · CALQUENCE · CAMCEVI · CARVYKTI · CYRAMZA · Cabometyx · Columvi · Copiktra · Cyclophosphamide · DARZALEX · Doptelet · ELIGARD · ELIQUIS · ELITEK · ELREXFIO · EMEND · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · EXKIVITY · Empaveli · Enhertu · Erleada · FOUNDATIONONE · FRUZAQLA · Fabhalta · Fulphila · GILOTRIF · GIVLAARI · Gel-One Cross-linked Hyaluronate · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Idhifa · Imbruvica · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Khapzory · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · MYRISK · Marqibo · NERLYNX · Nerlynx · Neulasta · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OGIVRI · OGSIVEO · OJJAARA · ONUREG · OPDIVO · ORGOVYX · OXBRYTA · Odomzo · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · Perjeta · Pomalyst · Poteligeo · QINLOCK · Quzyttir · REBLOZYL · RETEVMO · RYBREVANT · RYDAPT · Rezlidhia · Rubraca · SANCUSO · SANDOSTATIN · SANDOSTATIN LAR · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYNAGIS · Stivarga · Sylvant · TABRECTA · TAGRISSO · TASIGNA · TECVAYLI · TEPMETKO · TIBSOVO · Tavalisse · Tazverik · Tecentriq · Tibsovo · Tivdak · Trodelvy · ULTOMIRIS · VALCHLOR · VENCLEXTA · VERZENIO · VIVIMUSTA · VPRIV · VYXEOS · Venclexta · Vitrakvi · Vonjo · XALKORI · XPOVIO · XTANDI · XYNTHA · Xermelo · Xofigo · Xospata · Xtandi · YONSA · YONSA (abiraterone acetate) · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
7
Per 100K population
1.3
County median income
$64,403
Nearest hospital
MIAMI VALLEY HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Romer is a mixed practice specialist, with above-average Medicare volume (top 5% in OH), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Romer experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Romer performed 12,200 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Romer receive payments from pharmaceutical companies?
Yes. Dr. Romer received a total of $10,769 from 88 companies across 673 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Romer's costs compare to other medical oncologists in Dayton?
Dr. Romer's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Romer) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Dayton
Browse medical oncologists in Dayton ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in OH
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in OH
Which OH medical oncologists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Merck Sharp & Dohme LLC Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology